Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
deals
5
×
life sciences
national blog main
new york blog main
new york top stories
san francisco blog main
san francisco top stories
5
×
boston blog main
boston top stories
national top stories
startups
clinical trials
investing
biotech ipos
cancer immunotherapy
fda
national
san diego blog main
san diego top stories
san francisco
vc
10x genomics
acetylon pharmaceuticals
acute myeloid leukemia
alx oncology
ambys medicines
american society of clinical oncology (asco)
anti-inflammatory drugs
arcturus therapeutics
autoimmune diseases
avrobio
azacitidine
berkeley lights
beta-thalassemia
boston
boulder/denver blog main
boulder/denver top stories
brexanolone
camp4 therapeutics
What
biotech
5
×
new
companies
days
ipo
life
medicines
research
science
startup
street
today
wall
week
welcomed
ahead
aiming
aims
ambien
ambys
american
annual
approach
arrival
asco
attendees
attention
based
big
boost
called
camp’s
cancer
cash
chicago
city
clinical
combinations
community’s
control
Language
unset
Current search:
biotech
×
deals
×
" san francisco top stories "
×
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
